Anti-Cemiplimab Antibodies are introduced in Bio-Rad

Anti-Cemiplimab Antibodies are introduced in Bio-Rad ...

Bio-Rad Laboratories, a worldwide leader in life science research and clinical diagnostic equipment, has introduced a range of antibodies that are specific to cemiplimab (Libtayo) and inhibit the binding of the drug to its target, human-programmed death receptor-1, and are suitable for bioanalysis and drug monitoring.

Cemiplimab is a checkpoint inhibitor, which is blocking T cells'' interactions with the PD-1 antibody, as well as PD-L1 and PD-L2, and thus promoting T cells to be attacked by cancer cells. Three fully human IgG1 antibodies with varying affinity levels are ideal for site-directed conjugation or quick conversion to a bivalent Fab or an Ig-like format within an hour. ELISA is also available to use.

The recombinant antibodies are obtained using the Human Combinatorial Antibody Libraries (HuCAL) and CysDisplay, a proprietary technique of phage display, along with guided selection methods to obtain highly targeted reagents. The recombinant process results in batch-to-batch consistency, ensuring reproducible results and a secure supply throughout the assay lifecycle.

Bio-Rad''s long-term selection of recombinant, monoclonal, and anti-idiotypic antibodies continues to expand. These crucial antibody reagents help researchers in developing bioanalytical tests for checkpoint inhibitor drugs, according to Amanda Turner, a bio-Rad product manager. The addition of TrailBlazer Antibodies to the range allows for greater flexibility in bioanalytical assay design.

The anti-cemiplimab antibodies are approved for in vitro research purposes, and for commercial applications that are providing in vitro testing services to assist preclinical and clinical drugs and biosimilar development.

You may also like: